| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Negotiable |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
| Product Name | Lisinopril |
| Appearance | Lisinopril Powder |
| Assay | 99% |
| MW | 405.495 |
| MF | C21H31N3O5 |
Lisinopril can reduce pulmonary wedge pressure, increase cardiac output, increase left ventricular ejection fraction, and improve heart function in patients with heart failure. It can increase renal blood flow, reduce renal vascular resistance, and increase glomerular filtration rate. It can be used alone or in combination with other drugs to treat various degrees of hypertension and renal hypertension for which other antihypertensive drugs are ineffective. It can also be used alone or in combination with digitalis and diuretics to treat congestive heart failure. It can also be used as an adjuvant treatment for patients with stable hemodynamics after acute myocardial infarction.
Lenopril is a third generation angiotensin-converting enzyme inhibitor, a lysine derivative of Enalapril, which was marketed in the United States in 1987 for the treatment of hypertension and is the first-line treatment for anti-hypertensive disease. It is similar to Enalapril in terms of pharmacological action and has a strong angiotensin-converting enzyme inhibitory effect, with rapid onset and long duration of action. The inhibitory effect on ACE is 6-8 times that of captopril and 1-3 times that of benazepril. It can cause a significant decrease in total peripheral resistance and blood pressure, but is not accompanied by reflex tachycardia. Lenopril can lower pulmonary wedge pressure, increase cardiac beat volume, increase left ventricular ejection fraction and improve cardiac function in patients with heart failure. It can increase renal blood flow, reduce renal vascular resistance, and increase glomerular filtration rate.
){kind=link}